Waterlot C, Porchet N, Bauters C, Decoulx M, Wémeau J L, Proye C, Degand P M, Aubert J P, Cortet C, Dewailly D
Clinique Médicale Marc Linquette, CHRU, Lille; Faculté de médecine, Université de Lille II, Lille, France.
Clin Endocrinol (Oxf). 1999 Jul;51(1):101-7. doi: 10.1046/j.1365-2265.1999.00747.x.
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal genetic disorder, the clinical phenotype of which includes tumours of the parathyroids and/or anterior pituitary and/or endocrine pancreas. The genetic defect has been mapped to the chromosome 11q13 and the MEN1 gene has been recently identified, thus allowing genetic screening in affected kindreds. The aim of this study was to establish the usefulness of genetic screening in the follow-up of a large MEN1 kindred.
We describe a large kindred of 91 members, of whom 56 had clinical, biochemical and genetic screening. Twenty eight of them have been tested annually for the last 5 years.
Although the precise mutation is still undetermined in this kindred, genotypic determination confirmed linkage with the MEN1 gene in affected members and excluded 28 members from annual testing. By drawing our attention to susceptible subjects, genetic screening improved the evaluation of age-related penetrance of the disease in the 3 generations from this kindred. For instance, annual screening showed conversion from unaffected to affected phenotype in 4 subjects aged 14, 14, 15, and 17 years. Moreover, genetics helped us to evaluate the specificity of clinical or biochemical markers, and thus to discard useless investigations. So far however, the genetics have not helped to explain the phenotypic heterogeneity and particularly low incidence of pancreatic tumours in this kindred.
Genetic screening is very useful in detecting high risk individuals for MEN 1, since it avoids time-consuming and expensive investigations in non-affected subjects. By providing better understanding of the age-related penetrance of this syndrome, it improves the efficiency of screening. Genetic studies allow differentiation between clinical and biochemical features that are useful in follow-up and other confusing or unhelpful parameters.
多发性内分泌腺瘤1型(MEN1)是一种常染色体显性遗传病,其临床表型包括甲状旁腺和/或垂体前叶和/或内分泌胰腺肿瘤。该基因缺陷已被定位到11号染色体长臂1区3带,并且最近已鉴定出MEN1基因,从而能够对受累家族进行基因筛查。本研究的目的是确定基因筛查在一个大型MEN1家族随访中的作用。
我们描述了一个由91名成员组成的大家族,其中56人接受了临床、生化和基因筛查。在过去5年中,他们中的28人每年都接受检测。
尽管该家族的确切突变仍未确定,但基因型测定证实了受累成员与MEN1基因的连锁关系,并使28名成员无需每年进行检测。通过让我们关注易感个体,基因筛查改善了对该家族三代人中与年龄相关的疾病外显率的评估。例如,每年的筛查显示,4名年龄分别为14岁、14岁、15岁和17岁的个体从未受累表型转变为受累表型。此外,遗传学帮助我们评估临床或生化标志物的特异性,从而摒弃无用的检查。然而,到目前为止,遗传学尚未有助于解释该家族中表型异质性以及胰腺肿瘤发病率特别低的原因。
基因筛查在检测MEN1高危个体方面非常有用,因为它避免了对未受累个体进行耗时且昂贵的检查。通过更好地理解该综合征与年龄相关的外显率,它提高了筛查效率。基因研究能够区分对随访有用的临床和生化特征与其他混淆或无用的参数。